Last updated: April 25, 2026
What is TW200904419 (publication/patent record) and what does it claim?
TW200904419 is a Taiwan patent publication (publication year: 2009) that falls within the Taiwan drug patent register used for patentability and enforcement in Taiwan. A complete and accurate scope and claims analysis requires the full text of the publication record (claims set, specification summary, claim dependencies, and figure/embodiment support). With only the identifier provided, the claims and scope cannot be reproduced reliably.
No claim chart or scope breakdown can be produced without the actual claim language.
What is the scope of protection (claim types) for TW200904419?
A scope assessment must map each independent claim to:
- Claim category (compound, composition, formulation, method of treatment, use, process, or selection)
- Key structural or functional limitations (substituents, salts, polymorphs, stereochemistry, dose regimens, patient selection criteria)
- Dependency structure (how dependent claims narrow independent claim subject matter)
- Estoppel-risk areas (functional claiming that can read broadly vs. narrow Markush-style structural definitions)
- Enablement support tied to the written description (examples and definitions)
That mapping requires verbatim claim text from TW200904419. Without it, any attempt to infer scope would be non-actionable.
How broad is TW200904419 vs. typical Taiwan drug patent claim drafting?
A Taiwan drug patent’s practical breadth is usually driven by whether it claims:
- Single defined compounds (narrower, easier infringement but easier design-around)
- A family defined by Markush-like structural formulae (broader, but depends on the exact drafting and examples)
- Medical use (often broader in practice but constrained by Taiwan enablement and claim construction)
- Formulations/dosing regimens (often narrower, yet can create strong product barriers)
- Polymorphs/salts (can be narrow in chemistry but strong in enforcement)
Without the claim set for TW200904419, breadth comparison cannot be computed from facts.
What is the Taiwan patent landscape around TW200904419?
A landscape analysis in Taiwan has to be grounded in:
- Related Taiwan family members (same priority, continuation/divisional equivalents)
- Compound vs. formulation vs. method-of-use strategy across jurisdictions
- Patent term adjustments or Taiwan-specific procedural events that affect enforceability
- Regulatory linkage if the patent is listed under Taiwan’s drug regulatory mechanisms (where applicable)
- Expiry windows vs. generic entry timelines and court/administrative actions
Again, this must be built from actual publication data (assignee, priority date, other family publications, listed claims) and requires access to the bibliographic and claims text for TW200904419.
What actionable due diligence can be done for enforcement and FTO?
To support an FTO or enforcement decision for TW200904419, the operative deliverables are:
- A claim-by-claim infringement matrix tied to the competitor product dossier or planned formulation
- A design-around map showing which claim elements are likely to be the gating limitations
- A therapeutic scope analysis for method-of-use claims (if present)
- A compositions coverage analysis for salt/polymorph and excipient-defined formulations (if present)
- A validity risk scan driven by the claim language (novelty, inventive step, clarity, enablement)
None of these can be produced accurately without the claim text and key definitions in TW200904419.
Key takeaways
- TW200904419’s scope and claim language cannot be analyzed from the identifier alone.
- A reliable landscape view in Taiwan depends on the full TW200904419 publication record (claims, bibliographic data, and family links), which is not provided.
- Without the claims, any determination of breadth, priority/expiry posture, enforcement hooks, or generic design-around options would be speculative.
FAQs
1) Can I determine TW200904419’s exact claim scope without the claim text?
No. Scope must be derived from the verbatim claims and their dependencies.
2) What makes a Taiwan drug patent landscape analysis “complete”?
Family members, bibliographic data, claim categories, and the relationship to Taiwan regulatory listing/enforcement pathways.
3) How do independent vs. dependent claims drive enforcement risk?
Independent claims define the core infringement hooks; dependent claims narrow coverage and can indicate fallback positions during litigation.
4) What claim elements most often enable generic design-around?
Defined chemical structures or Markush boundaries (if chemical), specific salt/polymorph identifiers, dosing regimen boundaries (if method-of-use/regimen), and excipient definitions (if formulations).
5) What is the minimum dataset needed to produce a defensible landscape?
Full publication text (including claims) plus priority and family links.
References
[1] TW200904419, Taiwan patent publication record (publication 2009).
